Welcome and introduction
Patient Case Studies with short didactic and panel discussions
- How do you determine risk of progression for smoldering MM?
- When do you consider therapy for patients with smoldering MM?
- Introduction to the 2023 MM Care Algorithm: Diagnosis
- What induction therapy is optimal for patients with newly diagnosed MM?
- What should the ideal duration of therapy be for first-line MM?
- Introduction to the 2023 MM Care Algorithm: Newly Diagnosed MM
- When should you start treatment at first relapse?
- What strategy do you use to select therapy at first relapse?
- Introduction to the 2023 MM Care Algorithm: Treatment at First Relapse
- How do you select therapy for an “average” patient who has experienced multiple relapses?
- Case variation: What patient and disease factors would change your treatment approach?
- What therapy do you consider for patients after BCMA-targeted treatment?
- Introduction to the 2023 MM Care Algorithm: Treatment for Heavily Pretreated Disease
Program summary and closing
Date / Time
New Orleans, LA
Hyatt Regency New Orleans
Brian G.M. Durie, MD
Medical Director, AMyC
Co-Chair Myeloma Committee, SWOG
Chairman, International Myeloma Foundation
Specialist in Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California
Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Thomas G. Martin, MD
Clinical Professor of Medicine
Associate Director, Myeloma Program
University of California, San Francisco Medical Center
San Francisco, California
Philippe Moreau, MD
Professor of Clinical Hematology
Head, Hematology Department
University Hospital Hôtel-Dieu
S. Vincent Rajkumar, MD
Edward W. and Betty Knight Scripps
Professor of Medicine
Jesús F. San-Miguel, MD, PhD
Director of Clinical and Translational Medicine
Universidad de Navarra
The goal of this activity is to improve learners’ knowledge of and competence in applying practice-changing clinical data and expert recommendations to optimize the care of their patients with multiple myeloma.
This program is intended for physicians and other healthcare professionals who care for patients with multiple myeloma.
Upon completion of this activity, participants should be able to:
- Initiate timely systemic treatment for appropriate patients based on the latest multiple myeloma diagnostic criteria, staging criteria, and risk factors
- Develop individualized treatment strategies for patients with newly diagnosed multiple myeloma through consideration of the available clinical data as well as risk assessment, comorbidities, and patient age/fitness and preferences
- Appraise the efficacy and safety evidence of novel combination therapeutic regimens for patients with multiple myeloma
- Select optimal therapies for patients with heavily pretreated relapsed/refractory multiple myeloma based on individual patient and disease characteristics, as well as response to and tolerance of previous therapies
- Identify patients with relapsed/refractory multiple myeloma who would be eligible for enrollment on key ongoing clinical trials
- Recognize adverse events associated with new or novel multiple myeloma treatments
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.